Skip to content Skip to menu

In partnership with key stakeholders, Medicines Australia drives the creation and development of an environment for the continued sustainable growth of the innovative research based prescription medicines industry

About Us

Papers, Reports & Submissions


Agreements, Indemnity & Compensation Guidelines

Clinical Trials

Awards, Speeches & Media Releases

Media & Events

Member company lounge

Member's Area

Sign up for updates

Sign up for email updates to keep on top of Medicines Australia developments.

CEP Transcript Request

If you would like a transcript for courses completed prior to 2012, please complete the online enquiry form.


MA welcomes news from TGA, at @ARCSAustralia Conference - TGA has considered 3 applications for Priority Review designation and approved 2.

Pharmaceutical industry acknowledges service of Martin Bowles PSM.

RT @PharmaInFocusAu: Hunt praises departing #health secretary Martin Bowles for @MedicinesAus agreement @healthgovau

RT @ZarliFrench: Just 3 things could address the discrimination faced by people with rare cancers @RareCancers #CanForum17

Great announcement from @GregHuntMP: By 30 Sept there will open a call for proposals for CT's in rare cancers from $13m fund #CanForum2017

RT @MSD_Aus: Since focusing on #genderequality & #flexibleworking, MSD female sales managers numbers have increase significantly https://t.…

It's #JeansforGenesDay! We're throwing our support behind @cmri_research to help prevent childhood disease.…

State of the Sector Med Tech & Pharma report for Vic released at GSK today. Found sector generated $12.7 bn revenue.

PBAC announces appointment of industry expert to Committee

457 Visa modifications welcomed by pharmaceutical industry

RT @MTPConnect_AUS: New report estimates $1b VC investment—vital funds to commercialise research & drive new growth @A_Sinodinos https://t.…

RT @MSD_Aus: #Antimicrobial resistance is an important health issue - experts gather in Melbourne today to drive debate #AMR17 @ASIDANZ @Me

RT @pharmacydaily: @MedicinesAus major concerns about the King Interim #Pharmacy Review: lack of #competition, Non-TGA-approved #chemo #com